A new analysis of over 43,000 adults suggests GLP-1 drugs may lower blood pressure in ways that go beyond their known effects on weight loss. The findings were presented at the European Congress on Obesity in May 2026.
The meta-analysis looked at 32 phase 3 clinical trials. The average participant was 54 years old. About 59% of participants had high blood pressure at the start of the studies. They took GLP-1 medications for an average of 15 months.
Researchers found that for every 1% of body weight lost, participants saw a drop in their systolic blood pressure, which is the upper number in a blood pressure reading. The more weight a person lost, the more their blood pressure decreased. This link held true regardless of how long the study lasted, the participant’s starting weight, sex, or whether they had diabetes.
Weight loss and blood pressure
The connection between excess weight and high blood pressure is well known. This analysis puts a number on that link in the context of GLP-1 drugs. A 2024 analysis of three large clinical trials found that semaglutide, the active ingredient in Ozempic and Wegovy, lowered the upper number in blood pressure readings compared to a placebo. The results were consistent even in people who already had high blood pressure.
A separate 2024 review of 15 trials found similar blood pressure improvements along with significant weight loss in people taking GLP-1 drugs. A 2023 analysis of 61 clinical trials found that semaglutide produced the greatest blood pressure reduction of any medication studied.
Effects beyond weight
The researchers note that even without weight loss, these drugs may directly relax blood vessels, improve how the kidneys handle salt, and reduce stress signals in the body. All of these things can independently lower blood pressure. This means GLP-1 drugs and newer multi-hormone medications may work to lower blood pressure through two separate pathways. One pathway depends on weight loss. The other acts directly on the cardiovascular and renal systems.
This second pathway is still being studied. Its existence helps explain why some patients see blood pressure benefits that seem larger than what their weight loss alone would suggest. The newer multi-hormone medications target not just GLP-1 but also other hormone receptors. These drugs engage multiple hormonal pathways at once. Researchers are still working to understand which mechanisms are driving which effects.
Who this affects
Obesity and high blood pressure do not just happen together. They reinforce each other. They are converging public health problems that contribute to preventable heart disease and deaths. Clinical guidelines already support managing overweight and obesity as a central strategy for lowering blood pressure.
For the roughly 59% of trial participants who already had high blood pressure, the blood pressure lowering effect of these drugs was not just a side benefit. It was a meaningful outcome on its own. For people taking these medications mainly for weight loss, understanding this cardiovascular effect adds important context to the full picture of what these drugs are doing in the body.
This is especially relevant given how often obesity and metabolic problems overlap. Research has shown that visceral fat in particular carries risks that extend well beyond the cardiovascular system. This underscores why treating obesity comprehensively matters.
Limitations and next steps
The consistency of findings across 32 trials and more than 43,000 participants is hard to dismiss. But the current meta-analysis has limitations. It relied on trial-level data rather than individual patient-level data. There was variability across trials in populations and study design. Blood pressure was not the primary outcome in any of the included trials. Patients may have also changed their blood pressure medications, which could have affected results.
Several trials are currently underway to investigate these effects further. Studies in humans are focusing on the acute effects these drugs have on heart and blood vessel function, kidney physiology, and neurohormonal pathways.
The researchers say the findings add a new dimension to understanding GLP-1 drugs. They may be meaningful tools for blood pressure management, especially for the large number of people living with both obesity and high blood pressure. As ongoing trials fill in the picture, the case for GLP-1 drugs’ role in comprehensive heart care is getting stronger.
